Review: taking Coumadin and Neurontin together


Summary

Drug interactions are reported among people who take Coumadin and Neurontin together. This review analyzes the effectiveness and drug interactions between Coumadin and Neurontin. It is created by eHealthMe based on reports of 5,417 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Coumadin and Neurontin >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Coumadin

Coumadin has active ingredients of warfarin sodium. It is often used in atrial fibrillation/flutter. (latest outcomes from Coumadin 73,237 users)

Neurontin

Neurontin has active ingredients of gabapentin. It is often used in pain. (latest outcomes from Neurontin 56,860 users)

On Jul, 28, 2016

5,417 people who take Coumadin, Neurontin are studied.


Number of reports submitted per year:

Coumadin and Neurontin drug interactions.

Drug effectiveness over time:

Coumadin:
  • < 1 month: 25.0% - (1 of 4 people)
  • 1 - 6 months: 55.0% - (5 of 9 people)
  • 6 - 12 months: 41.0% - (7 of 17 people)
  • 1 - 2 years: 63.0% - (7 of 11 people)
  • 2 - 5 years: 52.0% - (13 of 25 people)
  • 5 - 10 years: 75.0% - (9 of 12 people)
  • 10+ years: 83.0% - (15 of 18 people)
  • not specified: 100.0% - (2 of 2 people)
Neurontin:
  • < 1 month: 0.0% - (0 of 11 people)
  • 1 - 6 months: 18.0% - (3 of 16 people)
  • 6 - 12 months: 18.0% - (2 of 11 people)
  • 1 - 2 years: 25.0% - (4 of 16 people)
  • 2 - 5 years: 28.0% - (7 of 25 people)
  • 5 - 10 years: 31.0% - (6 of 19 people)
  • 10+ years: 0.0% - (0 of 5 people)
  • not specified: 0.0% - (0 of 1 people)

Drug effectiveness by gender:

Coumadin:
  • female: 61.0% - (33 of 54 people)
  • male: 59.0% - (26 of 44 people)
Neurontin:
  • female: 20.0% - (12 of 58 people)
  • male: 21.0% - (10 of 46 people)

Drug effectiveness by age:

Coumadin:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 66.0% - (2 of 3 people)
  • 30-39: 75.0% - (3 of 4 people)
  • 40-49: 63.0% - (14 of 22 people)
  • 50-59: 61.0% - (11 of 18 people)
  • 60+: 56.0% - (29 of 51 people)
Neurontin:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 3 people)
  • 30-39: 50.0% - (2 of 4 people)
  • 40-49: 21.0% - (5 of 23 people)
  • 50-59: 14.0% - (3 of 21 people)
  • 60+: 22.0% - (12 of 53 people)

Most common drug interactions over time *:

< 1 month:
  • international normalised ratio increased
  • anaemia
  • myelodysplastic syndrome
  • thrombocytopenia
  • blood creatinine increased
  • nausea
  • drug ineffective
  • epistaxis
  • localised infection
  • abscess
1 - 6 months:
  • dyspnoea
  • chest pain
  • oedema peripheral
  • anaemia
  • cellulitis
  • international normalised ratio increased
  • cerebral infarction
  • activated partial thromboplastin time prolonged
  • balance disorder
  • pain
6 - 12 months:
  • dyspnoea
  • atrial fibrillation
  • aortic valve sclerosis
  • atrial flutter
  • cough
  • diabetic retinopathy
  • dizziness
  • flushing
  • myalgia
  • pigmented naevus
1 - 2 years:
  • anxiety
  • nephrogenic systemic fibrosis
  • pain in extremity
  • gangrene
  • pneumonia
  • pulmonary hypertension
  • cellulitis
  • cough
  • impaired healing
  • mental status changes
2 - 5 years:
  • pain
  • anxiety
  • drug ineffective
  • atrial fibrillation
  • peripheral sensory neuropathy
  • hypertension
  • amnesia
  • pleural effusion
  • pneumonia
  • suicide attempt
5 - 10 years:
  • cerebrovascular accident
  • depression
  • fall
  • cardiac disorder
  • fatigue - chronic
  • loss of consciousness
  • muscle spasms
  • muscle weakness
  • myocardial infarction
  • overdose
10+ years:
  • hives
  • itching
  • rash generalised
  • urticaria
  • renal impairment
  • coagulation time prolonged
  • dementia
  • disease progression
  • impaired memory
  • international normalised ratio increased
not specified:
  • pain
  • anxiety
  • dyspnoea
  • nausea
  • oedema peripheral
  • anaemia
  • fatigue
  • osteonecrosis of jaw
  • pain in extremity
  • fall

Most common drug interactions by gender *:

female:
  • pain
  • anxiety
  • nausea
  • fall
  • dyspnoea
  • osteonecrosis of jaw
  • oedema peripheral
  • fatigue
  • pain in extremity
  • back pain
male:
  • pain
  • anxiety
  • anaemia
  • dyspnoea
  • oedema peripheral
  • pneumonia
  • injury
  • fatigue
  • osteonecrosis of jaw
  • cardiac failure congestive

Most common drug interactions by age *:

0-1:
  • orthostatic hypotension
2-9:
  • abdominal pain
  • activated partial thromboplastin time prolonged
  • anaemia
  • gastric haemorrhage
  • international normalised ratio increased
10-19:
  • drug ineffective
  • nausea
  • blood cholesterol increased
  • blood sodium decreased
  • blood triglycerides increased
  • convulsion
  • depressed level of consciousness
  • encephalopathy
  • fatigue
  • international normalised ratio decreased
20-29:
  • pain
  • headache
  • dyspnoea
  • pain in extremity
  • vomiting
  • deep vein thrombosis
  • nephrogenic systemic fibrosis
  • oedema
  • oedema peripheral
  • skin disorder
30-39:
  • anxiety
  • pain
  • fatigue
  • depression
  • asthenia
  • pain in extremity
  • hypoaesthesia
  • pyrexia
  • weight decreased
  • dyskinesia
40-49:
  • pain
  • anxiety
  • pain in extremity
  • neuropathy peripheral
  • injury
  • osteonecrosis of jaw
  • oedema peripheral
  • nausea
  • abdominal pain
  • anaemia
50-59:
  • pain
  • anxiety
  • osteonecrosis of jaw
  • oedema peripheral
  • anaemia
  • depression
  • dyspnoea
  • fatigue
  • pneumonia
  • neuropathy peripheral
60+:
  • pain
  • fall
  • anxiety
  • dyspnoea
  • oedema peripheral
  • anaemia
  • nausea
  • asthenia
  • fatigue
  • cardiac failure congestive

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Coumadin and Neurontin?

Can you answer these questions?

More questions for: Coumadin, Neurontin

You may be interested in these reviews

More reviews for: Coumadin, Neurontin

On eHealthMe, Coumadin (warfarin sodium) is often used to treat atrial fibrillation/flutter. Neurontin (gabapentin) is often used to treat pain. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.